Your session is about to expire
← Back to Search
Avoiding Coffee for Atrial Fibrillation (DECAF Trial)
N/A
Recruiting
Led By Greg Marcus, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Sustained AF
Men and women ≥ 21 years of age
Must not have
Cardioversion for atrial flutter rather than AF
Recent cardiothoracic surgery in preceding 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will study the effect of coffee on Atrial Fibrillation recurrence.
Who is the study for?
This trial is for men and women over 21 who have atrial fibrillation, drink coffee daily, and are scheduled for electrical cardioversion. They must be willing to either abstain from or continue drinking coffee and attend follow-up calls. Exclusions include allergies to coffee, recent heart surgeries, pregnancy plans within six months, or participation in conflicting studies.
What is being tested?
The study tests the impact of coffee on atrial fibrillation by randomly assigning participants to two groups: one that avoids coffee and another that continues consumption post-electrical cardioversion. The goal is to see if avoiding or consuming coffee affects AF recurrence over a six-month period.
What are the potential side effects?
Since this trial involves lifestyle changes rather than medication, side effects may not be as pronounced but could include withdrawal symptoms like headaches or irritability for those stopping coffee.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have ongoing atrial fibrillation.
Select...
I am 21 years old or older.
Select...
I am scheduled for a procedure to correct my heart rhythm.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I had a procedure to correct heart rhythm due to atrial flutter, not AF.
Select...
I have had heart or chest surgery in the last 3 months.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants with Recurrent AF or AFlutter (Atrial Flutter)
Rate of AF or AFlutter Recurrence
Secondary study objectives
Other arrhythmia onset or recurrence
Severity in AF Symptoms
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: ConsumeExperimental Treatment1 Intervention
Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.
Group II: AvoidExperimental Treatment1 Intervention
Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,780 Total Patients Enrolled
11 Trials studying Atrial Fibrillation
5,049 Patients Enrolled for Atrial Fibrillation
Greg Marcus, MDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
301 Total Patients Enrolled
Chris Wong, MDPrincipal InvestigatorUniversity of California, San Francisco